LEPU Bio (02157) saw its share price surge more than 5% during the afternoon trading session, before settling at a 3.9% gain to HK$4.13, with trading turnover reaching HK$81.11 million.

The company recently announced its interim results for the six months ended June 30, 2026, reporting revenue of RMB 522 million, a year-on-year increase of 12.1%. Profit attributable to company shareholders stood at RMB 27.393 million, down 34.4% compared to the same period last year, with basic earnings per share of RMB 0.02.

In terms of domestic commercialization, the group generated approximately RMB 371.3 million in revenue from sales of its products Mei Youheng (Vibekotamab for injection) and Pu Youheng (Pucotenlimab injection). This figure represents more than double the sales achieved during the corresponding period in 2025, when the company recorded RMB 150.6 million for the six months ended June 30, 2025.

According to a research report from Guolian Minsheng Securities, LEPU Bio has successfully monetized its R&D capabilities through the global rights licensing of CMG901 to AstraZeneca and the ex-Greater China rights licensing of MRG007 to ArriVent. During the reporting period, the company recognized a total of RMB 149 million in milestone revenue from these CMG901 and MRG007 licensing transactions.

From a business model perspective, the company has successfully established and validated its domestic commercialization capabilities, while also nearing the completion of the full-cycle Business Development (BD) process for CMG901. This achievement positions LEPU Bio to drive continuous optimization of its revenue structure through the dual-engine approach of domestic commercialization and overseas licensing partnerships.